Eficacia y Seguridad de un Nutracéutico Bebible para la Caída del Cabello en Pacientes que Utilizan Agonistas de los Receptores GLP-1/GIP
Evaluación de la Eficacia y Seguridad de un Nutracéutico Bebible para Mejorar la Caída del Cabello en Pacientes Tratados con Agonistas del Receptor GLP-1/GIP: un Estudio Doble Ciego, Aleatorizado 1:1, Controlado con Placebo.
The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Madrid
-
Madrid, Madrid, España, 28006
- Reclutamiento
- Grupo Dermatologico Y Estetico Pedro Jaen S.A.
-
Contacto:
- Leyre Malet, PhD
- Número de teléfono: +34 617862464
- Correo electrónico: info@icmrresearch.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Female gender.
- Age >35 years.
- Initiation of treatment with a GLP-1/GIP agonist, or treatment duration < 3 months, as per routine clinical practice in the endocrinology clinic.
- Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
- Additional criteria to be included by the client.
Exclusion Criteria:
- Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
- Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
- Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
- Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
- Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
- Women who have used anti-hair loss products within the last 3 months.
- Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
- Women who have undergone hair transplantation within the 18 months prior to study initiation.
- Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
- Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
- Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.
- Additional exclusion criteria to be specified by the sponsor.
- Any condition that, in the investigator's opinion, makes participation in the study inappropriate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador de placebos: Brazo de placebo
|
Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile. |
|
Experimental: Brazo de Producto Activo
|
Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Hair loss
Periodo de tiempo: From baseline to Day 180.
|
• Patient Reported Outcome using the Hair Shedding Scale: will assess the degree of hair loss among participants. On the day of the visit, they will be shown an A4 sheet with six ranges: between 1 (minimal shedding) to 6 (copious hair shedding). Ref. Perera E and Sinclair R, 2017 |
From baseline to Day 180.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Hair loss
Periodo de tiempo: From baseline to Day 180.
|
Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours. |
From baseline to Day 180.
|
|
Body composition
Periodo de tiempo: From baseline to Day 180.
|
Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Body composition
Periodo de tiempo: From baseline to Day 180.
|
BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Body composition
Periodo de tiempo: From baseline to Day 180.
|
Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor |
From baseline to Day 180.
|
|
Serum iron level
Periodo de tiempo: From baseline to Day 180.
|
Serum iron concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Ferritin level
Periodo de tiempo: From baseline to Day 180.
|
Serum ferritin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Transferrin level
Periodo de tiempo: From baseline to Day 180.
|
Serum transferrin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Transferrin saturation
Periodo de tiempo: From baseline to Day 180.
|
Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples. |
From baseline to Day 180.
|
|
Serum zinc level
Periodo de tiempo: From baseline to Day 180.
|
Serum zinc concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
25-hydroxyvitamin D level
Periodo de tiempo: From baseline to Day 180.
|
Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum folate level
Periodo de tiempo: From baseline to Day 180.
|
Serum folate concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Vitamin B12 level
Periodo de tiempo: From baseline to Day 180.
|
Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum albumin level
Periodo de tiempo: From baseline to Day 180.
|
Serum albumin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Thyroid-stimulating hormone (TSH) level
Periodo de tiempo: From baseline to Day 180.
|
Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Free thyroxine (free T4) level
Periodo de tiempo: From baseline to Day 180.
|
Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Total testosterone level
Periodo de tiempo: From baseline to Day 180.
|
Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Free testosterone level
Periodo de tiempo: From baseline to Day 180.
|
Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Dehydroepiandrosterone sulfate (DHEA-S) level
Periodo de tiempo: From baseline to Day 180.
|
Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Sex hormone-binding globulin (SHBG) level
Periodo de tiempo: From baseline to Day 180.
|
Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Fasting glucose level
Periodo de tiempo: From baseline to Day 180.
|
Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Glycated hemoglobin (HbA1c)
Periodo de tiempo: From baseline to Day 180.
|
Glycated hemoglobin measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Fasting insulin level
Periodo de tiempo: From baseline to Day 180.
|
Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
HOMA-IR
Periodo de tiempo: From baseline to Day 180.
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values. |
From baseline to Day 180.
|
|
Total cholesterol level
Periodo de tiempo: From baseline to Day 180.
|
Total cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
HDL cholesterol level
Periodo de tiempo: From baseline to Day 180.
|
HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
LDL cholesterol level
Periodo de tiempo: From baseline to Day 180.
|
LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Triglyceride level
Periodo de tiempo: From baseline to Day 180.
|
Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Aspartate aminotransferase (AST) level
Periodo de tiempo: From baseline to Day 180.
|
AST concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Alanine aminotransferase (ALT) level
Periodo de tiempo: From baseline to Day 180.
|
ALT concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Gamma-glutamyl transferase (GGT) level
Periodo de tiempo: From baseline to Day 180.
|
GGT concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Blood urea level
Periodo de tiempo: From baseline to Day 180.
|
Blood urea concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
|
Serum creatinine level
Periodo de tiempo: From baseline to Day 180.
|
Serum creatinine concentration measured in blood samples using standard clinical laboratory methods. |
From baseline to Day 180.
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Self-assessment questionnaire
Periodo de tiempo: From baseline to Day 180.
|
Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition. |
From baseline to Day 180.
|
|
Food consumption frequency questionnaire (PREDIMED questionnaire)
Periodo de tiempo: From baseline to Day 180.
|
Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet. |
From baseline to Day 180.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- CT-ON-04
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .